Why Pilots Don't Scale: The Case for Pre-Protocol Invariants in Clinical Development

A leading global sponsor has publicly quantified a ceiling that most in the industry prefer to leave unspoken: after eighteen months of running one of the most disciplined innovation operating models in clinical development, site adoption of any given new tactic has reached only seventy-nine percent. The disclosure, made at the PanAgora Clinical Trial Innovation Summit (搜索)搜索该词条 this spring, names that figure as the weak point in an otherwise mature system—and in doing so, exposes a structural problem that better software alone cannot touch.

The sponsor's model engages nine to twelve months before first-patient-in, defines strategy at the project level, and measures adoption, effectiveness, and impact, stopping tactics that fail to deliver. It supports more than thirty projects across sixty to a hundred studies. By any benchmark, this is mature governance. Yet proving out a single tactic still takes two to three years, and site adoption sits stubbornly at seventy-nine percent.

"Rather than finding a technology and searching for a trial to test it on," a senior portfolio innovation leader at the sponsor told the summit, "the team now starts with the operational challenge." The instinct is exactly right. By the sponsor's own numbers, it is also not yet enough.

Sites Don't Reject Innovation. They Reject Variability.

Industry surveys indicate that research sites routinely operate more than twenty separate platforms in daily use, with most coordinators running three or more CTMS environments simultaneously. Every sponsor that arrives brings a new login, a new data model, and a new definition of "done." The cognitive tax compounds with every protocol and has nothing to do with whether the latest tool is effective.

That reframes the seventy-nine percent figure. It tracks something other than how persuasive an innovation is—it measures how much structural variability a site is asked to absorb before the innovation even arrives.

Why Pilots Fail

Innovation enters too late, into a substrate that is at once locked and unstable. By the time a new tactic arrives, the scientific, operational, and data-flow decisions are already frozen, and the architecture required for scale was compromised before anyone wrote the pilot charter. Innovation becomes decorative—a layer bolted onto a protocol never designed to support it. Each rollout demands its own re-mapping, re-validation, and re-negotiation. Run that across sixty to a hundred studies and the two-to-three-year scaling cycle is built by hand.

The substrate itself keeps growing less stable. Between 2010 and 2020, the data a single protocol collects roughly tripled while endpoints nearly doubled and investigative sites per trial rose sixty percent; the share of protocols carrying substantial amendments climbed from sixty-six to eighty-two percent. Each new layer is one more thing every future innovation must map itself onto.

The missing layer, according to the analysis, has a name: pre-protocol invariants—the stable, non-negotiable structural constraints that anchor data, workflow, and operational expectations across an entire portfolio, fixed before the first protocol is written. Lock them, and innovation finally has something solid to attach to. Skip them, and every attempt becomes a one-off integration problem solved from scratch.

The Five Invariants That Determine Whether Innovation Survives Scale

The framework identifies five invariants that must be locked before protocol design begins.

First, semantic and data-lineage invariants: definitions, transformations, and lineage must mean the same thing in every study across the portfolio. CDISC (搜索)搜索该词条's SDTM standardizes how data is tabulated for submission, but that is the end of the pipeline, not the start—it does not guarantee that two studies defined "response" the same way at capture. Without that consistency upstream, every new tool inherits a fresh re-mapping problem, the silent driver of the two-to-three-year scaling cycle.

Second, workflow decision-point invariants: operational logic must remain stable across studies. When decision boundaries—dose modification, discontinuation, escalation—drift from trial to trial, technology cannot integrate predictably because the thing it integrates with keeps moving.

Third, site-facing operational invariants: every new login, workflow, and data model adds cognitive load to a site already running more than twenty systems. Structural predictability—one identity layer, one support pathway, one interaction model—is the currency of site adoption, and its absence is the structural reason even best-in-class governance finds seventy-nine percent so hard to move.

Fourth, evidence-threshold invariants: pilots fail because success gets defined after the results are in. Predefined criteria for adoption, continuation, and termination make innovation measurable rather than narrative—a tactic either clears the bar set at T-12 or it does not.

Fifth, cross-functional accountability invariants: clear ownership nine to twelve months before first-patient-in is non-negotiable. Innovation collapses when accountability is distributed but responsibility is unclear: everyone owns it, so no one does.

Three Operational Tools

The framework is operationalized through three instruments.

The PPI-5 Checklist, applied at T-12 (twelve months before first-patient-in), consists of five yes/no questions addressing whether semantic invariants are locked, workflow boundaries are defined, the site interaction model is stable, evidence thresholds are set, and accountability is confirmed. Scoring: five out of five indicates structural readiness; three to four out of five signals scale risk requiring address before T-9; below three out of five means the pilot will not survive operational reality.

The Pilot Survivability Score (PSS) is a twenty-point scale rating each candidate tactic on four dimensions: semantic readiness, workflow stability, site predictability, and evidence thresholds, each scored zero to five. A PSS of sixteen or above indicates high survivability; ten to fifteen signals moderate risk requiring gap remediation; below ten is a kill signal, not a coaching opportunity.

The UIW-12 Governance Timeline maps the Upstream Innovation Window across twelve months: T-12 applies the PPI-5 checklist; T-9 scores tactics on PSS with kill-or-proceed decisions; T-6 harmonizes site-facing workflows; T-3 locks invariants and finalizes thresholds; T-0 validates adherence at study startup with an Invariant Adherence Audit.

The Path Forward

The sponsors who pull ahead, the analysis concludes, will be those that fix the substrate first—that lock their invariants while everyone else is still launching pilots. The sponsor at the PanAgora summit built the governance layer and proved its limits in public; the next advantage belongs to whoever builds the foundation beneath it. Everyone else will keep running the same experiment and posting the same seventy-nine percent—one pilot at a time.

The analysis was authored by Yogesh Kumar Gupta, a clinical data and standards management professional with seventeen years of experience across oncology, cardiovascular, neuroscience, and metabolic disease therapeutic areas.